• CMT-SORD: Share Your StoryCMT-SORD: Share Your Story
    CMT-SORD: What is Your Story? For many with CMT, the journey through diagnosis, acceptance, and living with this progressive disease can be isolating. Most research is conducted through a clinical lens that aims to improve symptoms. However, CMT does not affect ...
    Read more ...
  • Chris Oviatt – Golfer with CMTChris Oviatt - Golfer with CMT
    Chris Oviatt is a golfer from Oregon who was diagnosed with Charcot-Marie-Tooth disease (CMT) in 1987. As she prepares for the US Adaptive Open in Kansas, Chris took time to chat with CMTA’s CEO Dr. Sue Bruhn about her journey ...
    Read more ...
  • CMTA Announces New Center of Excellence in ThailandCMTA Announces New Center of Excellence in Thailand
    The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce it has awarded the CMTA Center of Excellence ...
    Read more ...
  • CMTA Appoints David Skarinsky to its Therapy Expert BoardCMTA Appoints David Skarinsky to its Therapy Expert Board
    The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research that’s aimed at bringing treatments and a cure to patients of this rare disease, is pleased to announce the appointment of David Skarinsky to its Strategy to ...
    Read more ...
  • NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT PatientsNMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients
    The Charcot-Marie-Tooth Association (CMTA) is excited to share that our Alliance Partner, NMD Pharma, has received clearance from the US Food and Drug Administration (FDA) to initiate a Phase II clinical trial for their investigational drug, NMD670, in patients with ...
    Read more ...